SIRPant Immunotherapeutics
SIRPant Immunotherapeutics is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at SIRPant Immunotherapeutics.
SIRPant Immunotherapeutics is a company.
Key people at SIRPant Immunotherapeutics.
SIRPant Immunotherapeutics is a clinical-stage immuno-oncology company developing macrophage-based cell therapies for hematological malignancies and solid tumors, primarily targeting cancers like head & neck, colon, lung, pancreatic, cutaneous T-cell lymphoma, non-Hodgkin lymphoma, and others.[1][2][3][6] Its lead product, SIRPant-M™, is an autologous therapy that engineers a patient's own monocytes into SIRPαlow activated macrophages (M1 phenotype) to promote polyclonal anti-tumor immune responses, eliminating cancer cells body-wide by activating T-cells and antibodies without genetic engineering.[1][2][4] This addresses unmet needs in oncology by offering simpler, less toxic, and cheaper manufacturing compared to engineered cell therapies, serving healthcare providers and patients with aggressive, treatment-resistant tumors.[1][3][4] Founded in 2020 and headquartered in Hummelstown, Pennsylvania, the company raised a $27M Series A in 2021, filed an IND in Q1 2023 (cleared by FDA), and initiated Phase 1 trials in H2 2023 for solid tumors and recurrent non-Hodgkin lymphoma, with plans for Series B funding to expand clinical work.[2][3][6]
SIRPant Immunotherapeutics was founded in 2020 as a Delaware C-Corporation headquartered in Pennsylvania's Hershey Center for Applied Research, emerging from research into macrophage activation to bypass the immunosuppressive tumor microenvironment.[1][2][4] The core idea stems from preclinical work showing SIRPαlow macrophages rapidly eliminate metastatic solid tumors in mice (e.g., pancreatic, colorectal, melanoma, lung, breast), achieving 100% survival rates by inducing long-lasting anti-cancer immunity via a simple blood draw, cell processing, and reinfusion process.[4] Key leadership includes Robert Towarnicki, MS, President & CEO, who presented at BIO 2023, and recently appointed Jelle Kijlstra, MD, MBA, Chief Medical Officer, with 30+ years in drug development.[2][3] Pivotal early moments include the 2021 $27M Series A raise and FDA IND clearance for SIRPant-M in early 2023, enabling first-in-human Phase 1 studies shortly after.[2][3]
SIRPant rides the macrophage therapy wave in immuno-oncology, shifting from T-cell-centric approaches (e.g., CAR-T) to innate immune cells like macrophages, which better penetrate solid tumor microenvironments suppressed by "don't eat me" signals like CD47-SIRPα.[1][4] Timing aligns with surging demand for next-gen cell therapies post-2020s CAR-T limitations in solids, amid a biotech funding rebound and FDA nods for similar platforms.[3] Market tailwinds include a $50B+ oncology cell therapy space growing 20%+ annually, driven by failures of checkpoint inhibitors in cold tumors, positioning SIRPant to fill gaps in pancreatic, lung, and lymphoma treatments.[2][6] By pioneering non-genetic macrophage tech, it influences the ecosystem toward simpler, scalable therapies, potentially accelerating adoption via partnerships and lowering barriers for community hospitals.[1][2]
SIRPant is poised for Phase 1 readouts in 2024-2025 on SIRPant-M efficacy in hard-to-treat solids and lymphomas, with Series B funding likely fueling multi-indication trials and combo studies (e.g., with PD-1 inhibitors).[2][3][6] Trends like AI-optimized cell engineering and bispecifics will amplify macrophage platforms, but SIRPant's non-GMO edge could drive faster scaling and acquisitions by big pharma seeking solid tumor breakthroughs. Its influence may grow by validating macrophages as a frontline modality, reshaping immuno-oncology from T-cell dominance toward innate-adaptive synergies—potentially delivering the body-wide responses that current therapies promise but struggle to achieve.[1][4]
Key people at SIRPant Immunotherapeutics.
